In REDEFINE 1, adverse events were mainly gastrointestinal (79.6% in the CagriSema group vs 39.9% with placebo) including nausea (55% vs 12.6%), constipation (30.7% vs 11.6%), and vomiting (26.1% vs 4.1%)
References Abufaraj M, Xu T, Cao C, Waldhoer T, Seitz C, Dandrea D, Siyam A, Tarawneh R, Fajkovic H, Schernhammer E, Yang L, Shariat SF (2021) Prevalence and trends in kidney stone among adults in the USA: analyses of National health and nutrition examination survey 20072018 data
Thyroid-Stimulating Hormone Receptor (TSHR) : TSHR is a G-protein-coupled receptor located on the surface of follicular epithelial cells
A programme of phase 3 trials with retatrutide (TRIUMPH) is ongoing with an aim to assess the safety and efficacy of retatrutide in different populations living with obesity (OSA, T2D, established cardiovascular disease, osteoarthritis)
doi: 10.1111/cen.12222 37 CetinkayaAKurutasEBBuyukbeseMAKantarcekenBBulbulogluE
